Price$28.17+8.85 (+45.81%)
2025-12-022026-03-09
News · 26 weeks380%
2025-12-072026-05-31
Mix390d
- Other1(33%)
- Offering1(33%)
- SEC Filings1(33%)
Latest news
25 items- SECGalecto Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Galecto, Inc. (0001800315) (Filer)
- PRGalecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 -- -- Strong financial position with approximately $535 million of cash and cash equivalents as of February 28, 2026, with anticipated runway into Phase 3 development of DMR-001 -- BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (Galecto or the Company) (NASDAQ:GLTO), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its name change to Damora Th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Galecto Inc.SCHEDULE 13G/A - Galecto, Inc. (0001800315) (Subject)
- PRGalecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by Galecto's independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Galecto in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 153,700 shares of the Galecto's common stock with a 10-year term and an exercise price of $29.58 per share
- PRGalecto to Participate in Leerink Partners 2026 Global Healthcare ConferenceBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET. A live webcast of the Company's presentation will be available under the "News & Events" tab in the Investor Calendar section of the Company's website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event. About Galecto, Inc. Galecto, Inc. is a clinical-stage biotechnology company advancing
- SECSEC Form SCHEDULE 13G filed by Galecto Inc.SCHEDULE 13G - Galecto, Inc. (0001800315) (Subject)
- ANALYSTUBS initiated coverage on Galecto with a new price targetUBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00
- PRGalecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 MillionBOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto. Jefferies, Leer
- INSIDERDirector Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)4 - Galecto, Inc. (0001800315) (Issuer)
- INSIDERDirector Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)4 - Galecto, Inc. (0001800315) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Galecto Inc.SCHEDULE 13D/A - Galecto, Inc. (0001800315) (Subject)
- SECSEC Form 8-K filed by Galecto Inc.8-K - Galecto, Inc. (0001800315) (Filer)
- SECSEC Form 424B5 filed by Galecto Inc.424B5 - Galecto, Inc. (0001800315) (Filer)
- PRGalecto Announces Pricing of $275 Million Underwritten Public OfferingBOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expec
- SECSEC Form 424B5 filed by Galecto Inc.424B5 - Galecto, Inc. (0001800315) (Filer)
- PRGalecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockBOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series C preferred stock will be convertible into 1,000 shares of common stock at
- SECSEC Form S-3ASR filed by Galecto Inc.S-3ASR - Galecto, Inc. (0001800315) (Filer)
- SECGalecto Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Galecto, Inc. (0001800315) (Filer)
- INSIDERChief Operating Officer Sattarzadeh Sherwin was granted 190,376 shares (SEC Form 4)4 - Galecto, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sattarzadeh Sherwin3 - Galecto, Inc. (0001800315) (Issuer)
- SECGalecto Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Galecto, Inc. (0001800315) (Filer)
- PRGalecto Highlights Key Strategic Priorities and Anticipated 2026 MilestonesDMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an
- INSIDERChief Medical Officer Hewes L. Becker was granted 264,629 shares (SEC Form 4)4 - Galecto, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hewes L. Becker3 - Galecto, Inc. (0001800315) (Issuer)
- ANALYSTLeerink Partners initiated coverage on Galecto with a new price targetLeerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00
GLTO FAQ
7 questionsWhat does Galecto Inc. do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for...Where does GLTO stock trade?
Galecto Inc. (GLTO) is listed on NASDAQ.What sector and industry is GLTO in?
Galecto Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Galecto Inc. go public?
Galecto Inc. (GLTO) completed its IPO in 2020.What are analysts saying about GLTO?
Galecto Inc. has had 4 recent analyst actions on file. The most recent action was from UBS: Buy with a $4500.00 price target on 2026-02-17.What companies are similar to GLTO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GLTO side-by-side with any of them on Quantisnow.How can I track GLTO on Quantisnow?
Quantisnow aggregates Galecto Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLTO to receive live email and push alerts on every new disclosure.